China's medical products administrator approved Simcere Pharmaceutical's (HKG:2096) clinical trial application for the SIM0686 drug for tumors, according to a Thursday filing with the Hong Kong bourse.
SIM0686 is intended for the treatment of advanced malignant tumors such as gastric and lung cancer, the filing said.
Shares jumped 3% during Thursday's morning trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.